Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers

Ravikanth Danda, Kalaivani Ganapathy, Gajanan Sathe, Anil K. Madugundu, Uma Maheswari Krishnan, Vikas Khetan, Pukhraj Rishi, Harsha Gowda, Akhilesh Pandey, Krishnakumar Subramanian, T. S.Keshava Prasad, Sailaja V. Elchuri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Retinoblastoma (RB) is a pediatric ocular cancer which is caused due to the aberrations in the RB1 gene. The changes in the membrane proteomics would help in understanding the development of the retinoblastoma and could identify candidates for biomarkers and therapy. Experimental design: Quantitative proteomics is performed on the enriched membrane fractions from pooled normal retina (n = 5) and pooled retinoblastoma tissues (n = 5). The proteins are tryptic-digested and tagged with iTRAQ labels. Orbitrap mass spectrometry is used to analyze and quantify the deregulated membrane proteins involved in the RB tumor progression. Immunohistochemistry (IHC) is used to further validate few of the differentially expressed proteins. Results: A total of 3122 proteins are identified of which, 663 proteins are found to be deregulated with ≥two fold change in the RB tumor compared to the retina. 282 proteins are upregulated and 381 are downregulated with ≥2 peptide identifications. Bioinformatic analysis revealed that, most of the proteins are involved in the transport, cellular communication, and growth. Overexpression of lamin B1 (LMNB1) and transferrin receptor (TFRC) are observed in RB tumors using IHC. Conclusion and clinical relevance: The present study, is the first comprehensive quantitative membrane proteomic atlas of the differentially regulated proteins in RB compared to the retina. LMNB1 and TFRC could be potential biomarkers for this childhood cancer.

Original languageEnglish (US)
Article number1700101
JournalProteomics - Clinical Applications
Volume12
Issue number5
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Retinoblastoma Protein
Retinoblastoma
Biomarkers
Proteome
Membranes
Proteomics
Retina
Proteins
Transferrin Receptors
Tumors
Eye Neoplasms
Immunohistochemistry
Neoplasms
Atlases
Cellular radio systems
Pediatrics
Tumor Biomarkers
Computational Biology
Bioinformatics
Aberrations

Keywords

  • LMNB1
  • mass spectrometry
  • membrane proteomics
  • retinoblastoma
  • TFRC

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Danda, R., Ganapathy, K., Sathe, G., Madugundu, A. K., Krishnan, U. M., Khetan, V., ... Elchuri, S. V. (2018). Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers. Proteomics - Clinical Applications, 12(5), [1700101]. https://doi.org/10.1002/prca.201700101

Membrane Proteome of Invasive Retinoblastoma : Differential Proteins and Biomarkers. / Danda, Ravikanth; Ganapathy, Kalaivani; Sathe, Gajanan; Madugundu, Anil K.; Krishnan, Uma Maheswari; Khetan, Vikas; Rishi, Pukhraj; Gowda, Harsha; Pandey, Akhilesh; Subramanian, Krishnakumar; Prasad, T. S.Keshava; Elchuri, Sailaja V.

In: Proteomics - Clinical Applications, Vol. 12, No. 5, 1700101, 01.09.2018.

Research output: Contribution to journalArticle

Danda, R, Ganapathy, K, Sathe, G, Madugundu, AK, Krishnan, UM, Khetan, V, Rishi, P, Gowda, H, Pandey, A, Subramanian, K, Prasad, TSK & Elchuri, SV 2018, 'Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers', Proteomics - Clinical Applications, vol. 12, no. 5, 1700101. https://doi.org/10.1002/prca.201700101
Danda R, Ganapathy K, Sathe G, Madugundu AK, Krishnan UM, Khetan V et al. Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers. Proteomics - Clinical Applications. 2018 Sep 1;12(5). 1700101. https://doi.org/10.1002/prca.201700101
Danda, Ravikanth ; Ganapathy, Kalaivani ; Sathe, Gajanan ; Madugundu, Anil K. ; Krishnan, Uma Maheswari ; Khetan, Vikas ; Rishi, Pukhraj ; Gowda, Harsha ; Pandey, Akhilesh ; Subramanian, Krishnakumar ; Prasad, T. S.Keshava ; Elchuri, Sailaja V. / Membrane Proteome of Invasive Retinoblastoma : Differential Proteins and Biomarkers. In: Proteomics - Clinical Applications. 2018 ; Vol. 12, No. 5.
@article{1e4e2c15e7874bc1a5b43f92bad3d43b,
title = "Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers",
abstract = "Purpose: Retinoblastoma (RB) is a pediatric ocular cancer which is caused due to the aberrations in the RB1 gene. The changes in the membrane proteomics would help in understanding the development of the retinoblastoma and could identify candidates for biomarkers and therapy. Experimental design: Quantitative proteomics is performed on the enriched membrane fractions from pooled normal retina (n = 5) and pooled retinoblastoma tissues (n = 5). The proteins are tryptic-digested and tagged with iTRAQ labels. Orbitrap mass spectrometry is used to analyze and quantify the deregulated membrane proteins involved in the RB tumor progression. Immunohistochemistry (IHC) is used to further validate few of the differentially expressed proteins. Results: A total of 3122 proteins are identified of which, 663 proteins are found to be deregulated with ≥two fold change in the RB tumor compared to the retina. 282 proteins are upregulated and 381 are downregulated with ≥2 peptide identifications. Bioinformatic analysis revealed that, most of the proteins are involved in the transport, cellular communication, and growth. Overexpression of lamin B1 (LMNB1) and transferrin receptor (TFRC) are observed in RB tumors using IHC. Conclusion and clinical relevance: The present study, is the first comprehensive quantitative membrane proteomic atlas of the differentially regulated proteins in RB compared to the retina. LMNB1 and TFRC could be potential biomarkers for this childhood cancer.",
keywords = "LMNB1, mass spectrometry, membrane proteomics, retinoblastoma, TFRC",
author = "Ravikanth Danda and Kalaivani Ganapathy and Gajanan Sathe and Madugundu, {Anil K.} and Krishnan, {Uma Maheswari} and Vikas Khetan and Pukhraj Rishi and Harsha Gowda and Akhilesh Pandey and Krishnakumar Subramanian and Prasad, {T. S.Keshava} and Elchuri, {Sailaja V.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/prca.201700101",
language = "English (US)",
volume = "12",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Membrane Proteome of Invasive Retinoblastoma

T2 - Differential Proteins and Biomarkers

AU - Danda, Ravikanth

AU - Ganapathy, Kalaivani

AU - Sathe, Gajanan

AU - Madugundu, Anil K.

AU - Krishnan, Uma Maheswari

AU - Khetan, Vikas

AU - Rishi, Pukhraj

AU - Gowda, Harsha

AU - Pandey, Akhilesh

AU - Subramanian, Krishnakumar

AU - Prasad, T. S.Keshava

AU - Elchuri, Sailaja V.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: Retinoblastoma (RB) is a pediatric ocular cancer which is caused due to the aberrations in the RB1 gene. The changes in the membrane proteomics would help in understanding the development of the retinoblastoma and could identify candidates for biomarkers and therapy. Experimental design: Quantitative proteomics is performed on the enriched membrane fractions from pooled normal retina (n = 5) and pooled retinoblastoma tissues (n = 5). The proteins are tryptic-digested and tagged with iTRAQ labels. Orbitrap mass spectrometry is used to analyze and quantify the deregulated membrane proteins involved in the RB tumor progression. Immunohistochemistry (IHC) is used to further validate few of the differentially expressed proteins. Results: A total of 3122 proteins are identified of which, 663 proteins are found to be deregulated with ≥two fold change in the RB tumor compared to the retina. 282 proteins are upregulated and 381 are downregulated with ≥2 peptide identifications. Bioinformatic analysis revealed that, most of the proteins are involved in the transport, cellular communication, and growth. Overexpression of lamin B1 (LMNB1) and transferrin receptor (TFRC) are observed in RB tumors using IHC. Conclusion and clinical relevance: The present study, is the first comprehensive quantitative membrane proteomic atlas of the differentially regulated proteins in RB compared to the retina. LMNB1 and TFRC could be potential biomarkers for this childhood cancer.

AB - Purpose: Retinoblastoma (RB) is a pediatric ocular cancer which is caused due to the aberrations in the RB1 gene. The changes in the membrane proteomics would help in understanding the development of the retinoblastoma and could identify candidates for biomarkers and therapy. Experimental design: Quantitative proteomics is performed on the enriched membrane fractions from pooled normal retina (n = 5) and pooled retinoblastoma tissues (n = 5). The proteins are tryptic-digested and tagged with iTRAQ labels. Orbitrap mass spectrometry is used to analyze and quantify the deregulated membrane proteins involved in the RB tumor progression. Immunohistochemistry (IHC) is used to further validate few of the differentially expressed proteins. Results: A total of 3122 proteins are identified of which, 663 proteins are found to be deregulated with ≥two fold change in the RB tumor compared to the retina. 282 proteins are upregulated and 381 are downregulated with ≥2 peptide identifications. Bioinformatic analysis revealed that, most of the proteins are involved in the transport, cellular communication, and growth. Overexpression of lamin B1 (LMNB1) and transferrin receptor (TFRC) are observed in RB tumors using IHC. Conclusion and clinical relevance: The present study, is the first comprehensive quantitative membrane proteomic atlas of the differentially regulated proteins in RB compared to the retina. LMNB1 and TFRC could be potential biomarkers for this childhood cancer.

KW - LMNB1

KW - mass spectrometry

KW - membrane proteomics

KW - retinoblastoma

KW - TFRC

UR - http://www.scopus.com/inward/record.url?scp=85053072979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053072979&partnerID=8YFLogxK

U2 - 10.1002/prca.201700101

DO - 10.1002/prca.201700101

M3 - Article

C2 - 29742327

AN - SCOPUS:85053072979

VL - 12

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 5

M1 - 1700101

ER -